The effect of curcumin in the treatment of NAFLD

Effect of curcumin on liver function enzymes in patients with NAFLD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014110511763N18

Enrollment

Registered

2015-01-18

Start date

2014-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Placebo

Intervention: curcumin, Capsules, 500 mg orally, once daily for 2 months

Control: placebo (bass calcium phosphate) Capsules 500 mg orally, once daily for 2 months

Intervention 1: Intervention: curcumin, Capsules, 500 mg orally, once daily for 2 months. Intervention 2: Control: placebo (bass calcium phosphate) Capsules 500 mg orally, once daily for 2 months.

Eligibility

Sex/Gender

All

Age

76 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: not suffering from diseases such as cardiovascular problems; kidney; lung; thyroid disorders and liver problems such as hepatitis; chronic liver disease; nonalcoholic fatty liver disease; Pregnant and milking ; BMW over 25; non-smoking and drugs such as celecoxib on inflammation. Exclusion criteria: patients with diseases such as cardiovascular problems; kidney; lung; thyroid disorders and liver problems such as hepatitis; chronic liver disease; nonalcoholic fatty liver disease; Become pregnant; smoking and drugs such as celecoxib on inflammation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
ALT. Timepoint: Before and after study. Method of measurement: Enzymatic photometric.;AST. Timepoint: Before and after study. Method of measurement: Enzymatic photometric.	—

Secondary

Measure	Time frame
TG. Timepoint: Before and after study. Method of measurement: Enzymatic.;Tch. Timepoint: Before and after study. Method of measurement: Enzymatic.;HDL. Timepoint: Before and after study. Method of measurement: Enzymatic.;LDL. Timepoint: Before and after study. Method of measurement: Fried Wald Equation equation.;Hs-CRP. Timepoint: Before and after study. Method of measurement: Aymynvasy sensitive enzymatic.;F.B.S. Timepoint: Before and after study. Method of measurement: Enzymatic.;HBA1C. Timepoint: Before and after study. Method of measurement: Enzymatic.	—

Measure

Time frame

TG. Timepoint: Before and after study. Method of measurement: Enzymatic.;Tch. Timepoint: Before and after study. Method of measurement: Enzymatic.;HDL. Timepoint: Before and after study. Method of measurement: Enzymatic.;LDL. Timepoint: Before and after study. Method of measurement: Fried Wald Equation equation.;Hs-CRP. Timepoint: Before and after study. Method of measurement: Aymynvasy sensitive enzymatic.;F.B.S. Timepoint: Before and after study. Method of measurement: Enzymatic.;HBA1C. Timepoint: Before and after study. Method of measurement: Enzymatic.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamReza Asgari doctor

Isfahan University of Medical Sciences

askari@mui.ac.ir+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 1, 2026